Prurigo

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Retrieved on: 
Monday, February 26, 2024

SAN CARLOS, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced a poster presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The poster highlights preclinical data detailing AK006’s mechanism of action and ability to reduce MRGPRX2-induced skin inflammation.

Key Points: 
  • The poster highlights preclinical data detailing AK006’s mechanism of action and ability to reduce MRGPRX2-induced skin inflammation.
  • Inappropriate mast cell activation, via IgE-dependent and IgE-independent pathways, has been implicated in the pathogenesis of multiple inflammatory skin diseases.
  • IgE-dependent mast cell activation has been identified as a pathogenic driver of chronic spontaneous urticaria and food allergy and agents which target this pathway have demonstrated therapeutic activity.
  • More recently, mast cell activation through MRGPRX2, an IgE independent mast cell activation pathway, has been implicated in the pathogenesis of chronic spontaneous urticaria, atopic dermatitis and prurigo nodularis.

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 4, 2024

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
  • “We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.

Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Retrieved on: 
Wednesday, February 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023.

Key Points: 
  • This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023.
  • Priority Review is granted for medicines that would significantly improve the treatment, diagnosis or prevention of serious conditions.
  • The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.
  • “The relentless itch experienced by many people living with prurigo nodularis and atopic dermatitis has a significant impact on their overall quality of life.

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023

HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment complete; topline data by YE 2023 -
    HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In July 2023, Celldex announced that enrollment to the CSU study (n=208) had been completed and that topline data is anticipated by the end of 2023.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2023 were $235.3 million compared to $252.7 million as of June 30, 2023.

Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis Patients

Retrieved on: 
Thursday, October 26, 2023

Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.

Key Points: 
  • Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.
  • Nemolizumab was well tolerated, and its safety profile was consistent with phase II trial results.1
    This press release features multimedia.
  • Results from the phase III OLYMPIA 2 trial will be submitted to selected health authorities around the world.
  • To learn more about prurigo nodularis, watch this video from the New England Journal of Medicine.

EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology

Retrieved on: 
Wednesday, October 4, 2023

Galderma, the emerging pure-play dermatology category leader, announced today it will be showcasing updates from across its broad and innovative dermatology portfolio at the 32nd European Academy of Dermatology and Venereology (EADV) congress in Berlin, October 11-14, 2023.

Key Points: 
  • Galderma, the emerging pure-play dermatology category leader, announced today it will be showcasing updates from across its broad and innovative dermatology portfolio at the 32nd European Academy of Dermatology and Venereology (EADV) congress in Berlin, October 11-14, 2023.
  • For more than 40 years, Galderma has focused exclusively on delivering advances in dermatology, and its extensive presence at this year’s congress underlines the true impact of its industry-leading expertise and ongoing commitment to cutting-edge science, brands and services.
  • “We’re so excited to share such an extensive range of new data at EADV this year, and for another opportunity to engage with the community of physicians attending.
  • Results from the phase IV START study reinforce Galderma’s confidence in the efficacy and safety of trifarotene vs. vehicle treatment at reducing atrophic acne scarring.

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023

HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment completed; topline data by YE 2023 -
    HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • In July 2023, Celldex announced that enrollment to the CSU study had been completed.
  • CSU EAACI 2023 Data Summary:
    At EAACI 2023 , data were presented on the complete 24 week experience for all patients.
  • In May 2023, Celldex announced that the first patient had been dosed in the Phase 1 study of CDX-585.

Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology

Retrieved on: 
Thursday, July 27, 2023

With its broad portfolio of leading brands and services, fueled by science-based innovation and focused commercial execution, Galderma is well positioned in a growing dermatology market.

Key Points: 
  • With its broad portfolio of leading brands and services, fueled by science-based innovation and focused commercial execution, Galderma is well positioned in a growing dermatology market.
  • Injectable Aesthetics delivered single-digit constant currency growth over the period, from a high comparative base in 2022.
  • While Galderma gained market share across its Injectable Aesthetic portfolio, Neuromodulators and Biostimulators stood out with double-digit constant currency growth for the period.
  • In the first half of 2023, Galderma continued to advance innovation, with significant launches and positive data presentations across its leading dermatology portfolio.

WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology

Retrieved on: 
Wednesday, June 28, 2023

Galderma will be presenting 59 abstracts/posters from across its extensive portfolio at the 25th World Congress of Dermatology (WCD), reflecting its unrelenting dedication to delivering innovative solutions to advance dermatology for every skin story.

Key Points: 
  • Galderma will be presenting 59 abstracts/posters from across its extensive portfolio at the 25th World Congress of Dermatology (WCD), reflecting its unrelenting dedication to delivering innovative solutions to advance dermatology for every skin story.
  • Galderma is the only pure-play dermatology company with more than 40 years of heritage, and its significant presence at the congress underscores its leadership in this space.
  • The WCD will take place in Singapore from July 3-8, 2023.
  • “The extent of our presence at the WCD this year – with nearly 60 abstracts/posters being presented – really exemplifies the strength of our dedication and offering in dermatology.

Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023

HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • “This quarter, we were excited to report additional positive data from our barzolvolimab Phase 1b multi-dose study in chronic spontaneous urticaria.
  • Celldex plans to initiate a Phase 2 international trial of barzolvolimab in eosinophilic esophagitis (EoE), the most common type of eosinophilic gastrointestinal disease, in June of 2023.
  • Revenues: Total revenue was $1.0 million in the first quarter of 2023, compared to $0.2 million for the comparable period in 2022.